Aimed Bio Inc. (KOSDAQ:0009K0)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Researches, Develops, Produces, and Sells Antibody-Based Therapeutics	171.21M	111.09M
Researches, Develops, Produces, and Sells Antibody-Based Therapeutics Growth	54.11%	-
Total	171.21M	111.09M
Total Growth	54.11%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
South Korea	171.21M	111.09M
South Korea Growth	54.12%	-
Total	171.21M	111.09M
Total Growth	54.12%	-

Source: S&P Global Market Intelligence.